111 related articles for article (PubMed ID: 3040246)
21. [A phase I trial of 4'-epiadriamycin].
Ogawa M; Ikeda K; Inagaki J; Horikoshi N; Inoue K; Nakada K; Usui N; Okada Y; Adachi K; Tada A
Gan To Kagaku Ryoho; 1984 Apr; 11(4):926-9. PubMed ID: 6586111
[TBL] [Abstract][Full Text] [Related]
22. [Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer or head and neck cancer].
Plasswilm L
Strahlenther Onkol; 2000 Dec; 176(12):583-4. PubMed ID: 11140154
[No Abstract] [Full Text] [Related]
23. Phase II study of 4'-epi-doxorubicin in advanced breast cancer.
Campora E; Nobile MT; Sertoli MR; Rosso R
Cancer Treat Rep; 1984 Oct; 68(10):1285-6. PubMed ID: 6597003
[No Abstract] [Full Text] [Related]
24. Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer.
Booser DJ; Esteva FJ; Rivera E; Valero V; Esparza-Guerra L; Priebe W; Hortobagyi GN
Cancer Chemother Pharmacol; 2002 Jul; 50(1):6-8. PubMed ID: 12111105
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of 4'-deoxydoxorubicin in patients with advanced breast cancer.
Leitner SP; Casper ES; Hakes TB; Kaufman RJ; Winn RJ; Scoppetuolo M; Raymond V; Geller NL; Young CW
Cancer Treat Rep; 1985 Nov; 69(11):1319-20. PubMed ID: 4092194
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of aclarubicin in non-small cell lung cancer.
Leiby JM; Hicks W; Roach RW; Neidhart JA
Cancer Treat Rep; 1987 Mar; 71(3):323-4. PubMed ID: 3028622
[No Abstract] [Full Text] [Related]
27. Mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer.
Soh LT; Tan EH; Ang PT
Singapore Med J; 1998 Aug; 39(8):357-8. PubMed ID: 9844496
[TBL] [Abstract][Full Text] [Related]
28. Clinical and molecular responses in lung cancer patients receiving Romidepsin.
Schrump DS; Fischette MR; Nguyen DM; Zhao M; Li X; Kunst TF; Hancox A; Hong JA; Chen GA; Kruchin E; Wright JJ; Rosing DR; Sparreboom A; Figg WD; Steinberg SM
Clin Cancer Res; 2008 Jan; 14(1):188-98. PubMed ID: 18172270
[TBL] [Abstract][Full Text] [Related]
29. [Amrubicin].
Shimizu T; Takada M; Yana T; Fukuoka M
Nihon Rinsho; 2002 May; 60 Suppl 5():374-7. PubMed ID: 12101692
[No Abstract] [Full Text] [Related]
30. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D
Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
[TBL] [Abstract][Full Text] [Related]
31. Phase II trial of 4'-deoxydoxorubicin (DxDx) in non-small cell lung cancer: a Cancer and Leukemia Group B Trial.
Ringenberg QS; Perry MC; Propert KJ; Modeas C; Hirsh V; Weiss RB; Richards F; Graziano S; Green M
Med Pediatr Oncol; 1988; 16(1):27-9. PubMed ID: 2828901
[TBL] [Abstract][Full Text] [Related]
32. Paclitaxel (1-hour infusion) plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter phase II trial.
Greco FA; Hainsworth JD
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-14-S12-17. PubMed ID: 9331113
[TBL] [Abstract][Full Text] [Related]
33. Phase II studies of polychemotherapy regimens in small cell lung cancer.
Eagan RT; Carr DT; Lee RE; Frytak S; Rubin J; Coles DT
Cancer Treat Rep; 1977; 61(1):93-5. PubMed ID: 861966
[No Abstract] [Full Text] [Related]
34. Phase II trial of anaxirone in advanced non-small cell lung cancer.
Fiebig HH; Henss H; Arnold H; von Bültzingslöwen F; Klee M; Queisser W; Peukert M
Cancer Treat Rep; 1987 May; 71(5):539-40. PubMed ID: 3567979
[No Abstract] [Full Text] [Related]
35. Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer.
Shepherd FA; Latreille J; Paul K; Eisenhauer E
Semin Oncol; 1996 Dec; 23(6 Suppl 16):84-90. PubMed ID: 9007130
[TBL] [Abstract][Full Text] [Related]
36. Phase I-II study of the continuous infusion of doxorubicin in the treatment of non-small cell lung cancer.
Green MD; Speyer JS; Bottino JC; Blum RH; Wernz JC; Muggia FM
Cancer Treat Rep; 1984 Apr; 68(4):681-2. PubMed ID: 6713422
[No Abstract] [Full Text] [Related]
37. A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer.
Marks RS; Graham DL; Sloan JA; Hillman S; Fishkoff S; Krook JE; Okuno SH; Mailliard JA; Fitch TR; Addo F
Am J Clin Oncol; 2003 Aug; 26(4):336-7. PubMed ID: 12902880
[TBL] [Abstract][Full Text] [Related]
38. Interrelationships between microvessel density, expression of VEGF and resistance to doxorubicin of non-small lung cell carcinoma.
Volm M; Koomägi R; Mattern J
Anticancer Res; 1996; 16(1):213-7. PubMed ID: 8615611
[TBL] [Abstract][Full Text] [Related]
39. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Herbst RS; Hammond LA; Carbone DP; Tran HT; Holroyd KJ; Desai A; Williams JI; Bekele BN; Hait H; Allgood V; Solomon S; Schiller JH
Clin Cancer Res; 2003 Sep; 9(11):4108-15. PubMed ID: 14519633
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer.
Choy H; Safran H; Akerley W; Graziano SL; Bogart JA; Cole BF
Clin Cancer Res; 1998 Aug; 4(8):1931-6. PubMed ID: 9717821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
